IP Library › Granted Patent US 12,384,770
Granted Patent B2
US 12,384,770 · App. 18/635,839 · Granted Aug 12, 2025

Heterocyclic compound

Inventors: Masahiro Ito (Kanagawa, JP); Hideyuki Sugiyama (Kanagawa, JP); Takeshi Yamamoto (Kanagawa, JP); Keiko Kakegawa (Kanagawa, JP); Jinxing Li (Kanagawa, JP); Junsi Wang (Kanagawa, JP); Takahito Kasahara (Kanagawa, JP); Masato Yoshikawa (Kanagawa, JP)
Assignee: Takeda Pharmaceutical Company Limited
C07D413/14A61P25/28C07D413/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,384,770
App. No.
18/635,839
Granted
Aug 12, 2025
Kind
B2
Abstract

The present invention provides a heterocyclic compound having a HDAC6 inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.

Claims (30)

1. A compound represented by the formula (I):

wherein

R 1 is

(1) a C 3-10 cycloalkyl group optionally substituted by 1 to 3 halogen atoms,

(2) a C 6-14 aryl group optionally substituted by 1 to 3 substituents selected from (i) a halogen atom, (ii) a cyano group, and (iii) a C 1-6 alkyl group optionally substituted by 1 to 3 halogen atoms,

(3) a 5- or 6-membered monocyclic aromatic heterocyclic group optionally substituted by 1 to 3 substituents selected from (i) a halogen atom, (ii) a C 1-6 alkyl group optionally substituted by 1 to 3 halogen atoms, and (iii) a C 1-6 alkoxy group, or

(4) a 3- to 8-membered monocyclic non-aromatic heterocyclic group, and

R 2 is

(1) a C 3-10 cycloalkyl group optionally substituted by 1 to 3 halogen atoms,

(2) a C 6-14 aryl group optionally substituted by 1 to 3 substituents selected from (i) a halogen atom, and (ii) a C 1-6 alkyl group optionally substituted by 1 to 3 halogen atoms,

(3) a 5- or 6-membered monocyclic aromatic heterocyclic group optionally substituted by 1 to 3 substituents selected from (i) a halogen atom, (ii) a C 1-6 alkyl group optionally substituted by 1 to 3 halogen atoms, and (iii) a C 1-6 alkoxy group, or

(4) a 3- to 8-membered monocyclic non-aromatic heterocyclic group,

or a salt thereof.

2. The compound or salt according to claim 1 , which is represented by the formula (I′):

wherein each symbol is as defined in claim 1 .

3. The compound or salt according to claim 1 , wherein

R 1 is

(1) a C 3-10 cycloalkyl group optionally substituted by 1 to 3 halogen atoms, or

(2) a 5- or 6-membered monocyclic aromatic heterocyclic group optionally substituted by 1 to 3 substituents selected from (i) a halogen atom, (ii) a C 1-6 alkyl group optionally substituted by 1 to 3 halogen atoms, and (iii) a C 1-6 alkoxy group, and

R 2 is

(1) a C 6-14 aryl group optionally substituted by 1 to 3 substituents selected from (i) a halogen atom, and (ii) a C 1-6 alkyl group optionally substituted by 1 to 3 halogen atoms, or

(2) a 5- or 6-membered monocyclic aromatic heterocyclic group optionally substituted by 1 to 3 substituents selected from (i) a halogen atom, (ii) a C 1-6 alkyl group optionally substituted by 1 to 3 halogen atoms, and (iii) a C 1-6 alkoxy group.

4. The compound or salt according to claim 1 , wherein

R 1 is

(1) a C 3-10 cycloalkyl group, or

(2) a 6-membered monocyclic aromatic heterocyclic group optionally substituted by 1 to 3 halogen atoms, and

R 2 is

(1) a C 6-14 aryl group optionally substituted by 1 to 3 halogen atoms, or

(2) a 6-membered monocyclic aromatic heterocyclic group optionally substituted by 1 to 3 halogen atoms.

5. A pharmaceutical composition comprising the compound or salt according to claim 1 and a pharmaceutically acceptable carrier.

Priority Claims (1)
JP 2019-177815 · Sep 27, 2019 · national
Continuity (3)
Division 17952546 · Sep 26, 2022
Division 17030504 · Sep 24, 2020
Related Publication 20240343721A1 · Oct 17, 2024
References Cited (193)
US 7250504B2 · Grozinger et al. · 2007 [cited by applicant]
US 7879865B2 · Richon et al. · 2011 [cited by applicant]
US 8026260B2 · Close et al. · 2011 [cited by applicant]
US 8067472B2 · Richon et al. · 2011 [cited by applicant]
US 8076116B2 · Grozinger et al. · 2011 [cited by applicant]
US 8088951B2 · Tsai et al. · 2012 [cited by applicant]
US 8389553B2 · Harrington et al. · 2013 [cited by applicant]
US 8435780B2 · Grozinger et al. · 2013 [cited by applicant]
US 8895284B2 · Grozinger et al. · 2014 [cited by applicant]
US 8901156B2 · Baloglu et al. · 2014 [cited by applicant]
US 8981084B2 · Baloglu et al. · 2015 [cited by applicant]
US 8999289B2 · Anderson et al. · 2015 [cited by applicant]
US 9056843B2 · Hebach et al. · 2015 [cited by applicant]
US 9096559B2 · Harrington et al. · 2015 [cited by applicant]
US 9238028B2 · Van Den Bosch et al. · 2016 [cited by applicant]
US 9365498B2 · Holson et al. · 2016 [cited by applicant]
US 9447030B2 · Holson et al. · 2016 [cited by applicant]
US 9480673B2 · Freed et al. · 2016 [cited by applicant]
US 9512083B2 · Raje et al. · 2016 [cited by applicant]
US 9572854B2 · Anderson et al. · 2017 [cited by applicant]
US 9670193B2 · Hebach et al. · 2017 [cited by applicant]
US 9890172B2 · Holson et al. · 2018 [cited by applicant]
US 10130604B2 · Freed et al. · 2018 [cited by applicant]
US 10172905B1 · Anderson et al. · 2019 [cited by applicant]
US 10406146B2 · Kaieda et al. · 2019 [cited by applicant]
US 10584117B2 · Lee et al. · 2020 [cited by applicant]
US 11453661B2 · Ito · 2022 [cited by examiner]
US 20030129724A1 · Grozinger et al. · 2003 [cited by applicant]
US 20040077591A1 · Dangond · 2004 [cited by applicant]
US 20040087657A1 · Richon et al. · 2004 [cited by applicant]
US 20040142859A1 · Steffan et al. · 2004 [cited by applicant]
US 20050009030A1 · Schweighoffer et al. · 2005 [cited by applicant]
US 20050227915A1 · Steffan et al. · 2005 [cited by applicant]
US 20060018921A1 · Levenson et al. · 2006 [cited by applicant]
US 20060135612A1 · Ferrante · 2006 [cited by applicant]
US 20070078083A1 · Barlow et al. · 2007 [cited by applicant]
US 20070207950A1 · Yao et al. · 2007 [cited by applicant]
US 20080114069A1 · Richon et al. · 2008 [cited by applicant]
US 20080221192A1 · Wan et al. · 2008 [cited by applicant]
US 20090036318A1 · Grozinger et al. · 2009 [cited by applicant]
US 20090136461A1 · Kim et al. · 2009 [cited by applicant]
US 20100004156A1 · Kaushal et al. · 2010 [cited by applicant]
US 20100022514A1 · Cho et al. · 2010 [cited by applicant]
US 20100247543A1 · Maes et al. · 2010 [cited by applicant]
US 20100292169A1 · Yao et al. · 2010 [cited by applicant]
US 20110124731A1 · Richon et al. · 2011 [cited by applicant]
US 20120039909A1 · Tsai et al. · 2012 [cited by applicant]
US 20120041067A1 · Richon et al. · 2012 [cited by applicant]
US 20120289495A1 · Baloglu et al. · 2012 [cited by applicant]
US 20130059883A1 · Baloglu et al. · 2013 [cited by applicant]
US 20130116204A1 · Schafer et al. · 2013 [cited by applicant]
US 20130203735A1 · Sisko et al. · 2013 [cited by applicant]
US 20130225543A1 · Jones et al. · 2013 [cited by applicant]
US 20130227717A1 · Van Den Bosch et al. · 2013 [cited by applicant]
US 20130317003A1 · Jacques et al. · 2013 [cited by applicant]
US 20140051680A1 · Jacques et al. · 2014 [cited by applicant]
US 20140080800A1 · Holson et al. · 2014 [cited by applicant]
US 20140080802A1 · Holson et al. · 2014 [cited by applicant]
US 20140235649A1 · Kovach et al. · 2014 [cited by applicant]
US 20140329825A1 · Hebach et al. · 2014 [cited by applicant]
US 20140378385A1 · Raje et al. · 2014 [cited by applicant]
US 20150038534A1 · Baloglu et al. · 2015 [cited by applicant]
US 20150119327A1 · Muotri et al. · 2015 [cited by applicant]
US 20150158884A1 · Jacques et al. · 2015 [cited by applicant]
US 20150184154A1 · Matthias et al. · 2015 [cited by applicant]
US 20160000766A1 · Van Den Bosch et al. · 2016 [cited by applicant]
US 20160221972A1 · Zheng et al. · 2016 [cited by applicant]
US 20160221973A1 · Zheng et al. · 2016 [cited by applicant]
US 20160222022A1 · Zheng et al. · 2016 [cited by applicant]
US 20160222028A1 · Zheng et al. · 2016 [cited by applicant]
US 20160251351A1 · Holson et al. · 2016 [cited by applicant]
US 20160347761A1 · Holson et al. · 2016 [cited by applicant]
US 20170015655A1 · Kaieda et al. · 2017 [cited by applicant]
US 20170044186A1 · Jacques et al. · 2017 [cited by applicant]
US 20170050984A1 · Jacques et al. · 2017 [cited by applicant]
US 20170096405A1 · Song et al. · 2017 [cited by applicant]
US 20170217955A9 · Holson et al. · 2017 [cited by applicant]
US 20170305866A1 · Raje et al. · 2017 [cited by applicant]
US 20180016282A9 · Holson et al. · 2018 [cited by applicant]
US 20180016314A1 · Harley et al. · 2018 [cited by applicant]
US 20180099977A1 · Holson et al. · 2018 [cited by applicant]
US 20180208606A1 · Jacques et al. · 2018 [cited by applicant]
US 20180230113A1 · Lee et al. · 2018 [cited by applicant]
US 20180256572A1 · Yates · 2018 [cited by applicant]
US 20180273495A1 · Kim et al. · 2018 [cited by applicant]
US 20180327423A1 · Jacques et al. · 2018 [cited by applicant]
US 20180370987A1 · Jacques et al. · 2018 [cited by applicant]
US 20190016692A1 · Zheng et al. · 2019 [cited by applicant]
US 20190016693A1 · Zheng et al. · 2019 [cited by applicant]
US 20190038589A1 · Freed et al. · 2019 [cited by applicant]
US 20190062288A1 · Zheng et al. · 2019 [cited by applicant]
US 20190112279A1 · Zheng et al. · 2019 [cited by applicant]
US 20190112280A1 · Zheng et al. · 2019 [cited by applicant]
US 20190112281A1 · Zheng et al. · 2019 [cited by applicant]
US 20190112282A1 · Zheng et al. · 2019 [cited by applicant]
US 20190112283A1 · Zheng et al. · 2019 [cited by applicant]
US 20190112284A1 · Zheng et al. · 2019 [cited by applicant]
US 20190119227A1 · Zheng et al. · 2019 [cited by applicant]
US 20190119228A1 · Zheng et al. · 2019 [cited by applicant]
US 20190119229A1 · Zheng et al. · 2019 [cited by applicant]
US 20190119230A1 · Zheng et al. · 2019 [cited by applicant]
US 20190119231A1 · Zheng et al. · 2019 [cited by applicant]
US 20190119232A1 · Zheng et al. · 2019 [cited by applicant]
US 20190119233A1 · Zheng et al. · 2019 [cited by applicant]
US 20190119234A1 · Zheng et al. · 2019 [cited by applicant]
US 20190119235A1 · Zheng et al. · 2019 [cited by applicant]
US 20190127339A1 · Zheng et al. · 2019 [cited by applicant]
US 20190135799A1 · Ito et al. · 2019 [cited by applicant]
US 20190233439A1 · Jacques et al. · 2019 [cited by applicant]
US 20200002298A1 · Zheng et al. · 2020 [cited by applicant]
US 20200048211A1 · Zheng et al. · 2020 [cited by applicant]
US 20200048212A1 · Zheng et al. · 2020 [cited by applicant]
US 20200055830A1 · Zheng et al. · 2020 [cited by applicant]
US 20200148704A1 · Jacques et al. · 2020 [cited by applicant]
US 20200354338A1 · Jin et al. · 2020 [cited by applicant]
US 20210009538A1 · Zheng et al. · 2021 [cited by applicant]
US 20210009539A1 · Zheng et al. · 2021 [cited by applicant]
US 20210009540A1 · Zheng et al. · 2021 [cited by applicant]
US 20220204461A1 · Zheng et al. · 2022 [cited by applicant]
US 20220235035A1 · Jin et al. · 2022 [cited by applicant]
US 20220363651A1 · Zheng et al. · 2022 [cited by applicant]
US 20230021554A1 · Jin et al. · 2023 [cited by applicant]
US 20230023761A1 · Jin et al. · 2023 [cited by applicant]
AU 2013203735A1 · 2013 [cited by applicant]
AU 2016338118B2 · 2017 [cited by applicant]
CN 101056632A · 2007 [cited by applicant]
CN 102770412A · 2012 [cited by applicant]
CN 105120860A · 2015 [cited by applicant]
CN 106232584A · 2016 [cited by applicant]
CN 107873023A · 2018 [cited by applicant]
CN 107980040A · 2018 [cited by applicant]
CN 108026088A · 2018 [cited by applicant]
EP 1390491B1 · 2004 [cited by applicant]
EP 1746982 · 2007 [cited by applicant]
EP 2624832 · 2013 [cited by applicant]
EP 3187497A1 · 2017 [cited by applicant]
EP 3327019 · 2018 [cited by applicant]
WO WO2005105066A2 · 2005 [cited by applicant]
WO WO2007049262 · 2007 [cited by applicant]
WO WO2007147868 · 2007 [cited by applicant]
WO WO2008073733 · 2008 [cited by applicant]
WO WO2008126932 · 2008 [cited by applicant]
WO WO2013006408A1 · 2013 [cited by applicant]
WO WO2013009810A1 · 2013 [cited by applicant]
WO WO2013009827A1 · 2013 [cited by applicant]
WO WO2013009830 · 2013 [cited by applicant]
WO WO2013066831A1 · 2013 [cited by applicant]
WO WO2013066833A1 · 2013 [cited by applicant]
WO WO2013066835A1 · 2013 [cited by applicant]
WO WO2013066838A1 · 2013 [cited by applicant]
WO WO2013066839A2 · 2013 [cited by applicant]
WO WO2015131788 · 2015 [cited by applicant]
WO WO2016039398 · 2016 [cited by applicant]
WO WO2017018803A1 · 2017 [cited by applicant]
WO WO2017018804A1 · 2017 [cited by applicant]
WO WO2017018805A1 · 2017 [cited by applicant]
WO WO2017023133A2 · 2017 [cited by applicant]
WO WO2017033946A1 · 2017 [cited by applicant]
WO WO2017222952A1 · 2017 [cited by applicant]
WO WO2018165520A1 · 2018 [cited by applicant]
WO WO2018215597 · 2018 [cited by applicant]
WO WO2019027054A1 · 2019 [cited by applicant]
WO WO2019030692 · 2019 [cited by applicant]
WO WO2019032652 · 2019 [cited by applicant]
WO WO2020022794 · 2020 [cited by applicant]
WO WO2020158762 · 2020 [cited by applicant]
Azad et al. “The future of epigenetic therapy in solid tumours-lessons from the past,” Nat. Rev. Clin. Oncol., Apr. 2, 2013, 10:256-266. [cited by applicant]
Chuang et al., “Multiple roles of HDAC inhibition in neurodegenerative conditions,” Trends in Neurosciences, 2009, 32(11):591-601. [cited by applicant]
Chung et al., “A Therapeutic Strategy Uses Histone Deacetylase Inhibitors to Modulate the Expression of Genes Involved in the Pathogenesis of Rheumatoid Arthritis,” Molecular Therapy, Nov. 2003, 8(5):707-717. [cited by applicant]
De Zoeten et al., “Histone Deacetylase 6 and Heat Shock Protein 90 Control the Functions of Foxp3 T-Regulatory Cells,” Molecular and Cellular Biology, May 2011, 31(10):2066-2078. [cited by applicant]
Dubey et al., “Neurodegeneration and microtubule dynamics: death by a thousand cuts,” Frontiers in Cellular Neuroscience, Sep. 9, 2015, 9(343):1-15. [cited by applicant]
Glauben et al., “Histone Hyperacetylation is Associated with Amelioration of Experimental Colitis in Mice,” The Journal of Immunology, 2006, 176:5015-5022. [cited by applicant]
Goedert et al., “Frontotemporal Dementia: Implications for Understanding Alzheimer Disease,” Cold Spring Harbor Perspectives in Medicine, 2012 (online Nov. 22, 2011), 4:a006254, 1-21. [cited by applicant]
Gouindarajan et al., “Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease,” EMBO Mol. Med., 2013, 5:52-63. [cited by applicant]
Haberland et al., “The many roles of histone deacetylases in development and physiology: implications for disease and therapy,” Nature Reviews Genetics, Jan. 2009, 10:32-42. [cited by applicant]
Hancock et al., “HDAC inhibitor therapy in autoimmunity and transplantation,” Ann. Rheum. Dis., 2012, 71(Supp.II):i46-i54. [cited by applicant]
Hubbert et al., “HDAC6 is a microtube-associated deacetylase,” Nature, May 23, 2002, 417:455-458. [cited by applicant]
Jin et al., “Design, synthesis and preliminary biological evaluation of indoline-2,3-dione derivatives as novel HDAC inhibitors,” Bioorganic & Medicinal Chemistry, 2015, 23:4728-4736. [cited by applicant]
Jochems et al., “Antidepressant-Like Properties of Novel HDAC6-Selective Inhibitors with Improved Brain Bioavailability,” Neuropsychopharmacology, 2014, 39:389-400. [cited by applicant]
Kalin et al., “Development and Therapeutic Implications of Selective Histone Deacetylase 6 Inhibitors,” Journal of Medicinal Chemistry, Apr. 29, 2013, 56:6297-6313. [cited by applicant]
Leroux, Michel R., “Tubulin acetyltransferase discovered: Ciliary role in the ancestral eukaryote expanded to neurons in metazoans,” PNAS, Dec. 14, 2020, 107(50):21238-21239. [cited by applicant]
Li et al., “HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen,” PNAS, Mar. 25, 2008, 105(12):4796-4801. [cited by applicant]
Ligand-Protein Interactions and Molecular Similarity, H. Kubinyi, Ed., Springer, 1998, vol. 2-3, 243-244. [cited by applicant]
Lin et al., “Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents,” British Journal of Pharmacology, 2007, 150:862-872. [cited by applicant]
Liu et al., “Histone deacetylase 6: structure, functions and development of selective inhibitors,” Acta Pharmaceutica Sinica, 2015, 50(1):7-14. [cited by applicant]
Lu et al., Journal of International Neurology and Neurosurgery, Dec. 31, 2011, 348-352, with English abstract. [cited by applicant]
Ma et al., “Selective histone deacetylase 6 inhibitors: research advances,” J. Int. Pharm. Res., Nov. 2018, 45(11):824-833, with English abstract. [cited by applicant]
Morfini et al., “Fast Axonal Transport Misregulation and Alzheimer's Disease,” NeuroMolecular Medicine, 2002, 2:89-99. [cited by applicant]
Santo et al., “Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma,” Blood, 2012, 119(11):2579-2589. [cited by applicant]
Selenica et al., “Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition,” Alzheimer's Research & Therapy, 2014, 6:12. [cited by applicant]
Shakespear et al., “Histone deacetylases as regulators of inflammation and immunity,” Trends in Immunology, Jul. 2011, 32(7):335-343. [cited by applicant]
The Practice of Medicinal Chemistry, 2nd. Ed., Wermuth, Ed., 2003, Chapters 9 and 10:131-157. [cited by applicant]
West et al., “New and emerging HDAC inhibitors for cancer treatment,” The Journal of Clinical Investigation, Jan. 2014, 124(1):30-39. [cited by applicant]